You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Profile for Ukraine Patent: 98133


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Ukraine Patent: 98133

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,763,954 Sep 13, 2028 Sumitomo Pharma Am APTIOM eslicarbazepine acetate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Ukraine Drug Patent UA98133

Last updated: August 6, 2025


Introduction

Patent UA98133 pertains to a pharmaceutical invention protected under Ukrainian intellectual property law. To develop a comprehensive understanding, this analysis delves into the scope of the patent, the detailed claims it comprises, and its position within the broader patent landscape of medicinal innovations. This review aids stakeholders—researchers, pharmaceutical companies, and legal professionals—in assessing the patent’s strength, potential for licensing, or infringement risk.


Patent Overview and Filing Context

Ukraine’s patent UA98133 was filed on [specific filing date if available], with patent protection granted on [grant date if available]. It exemplifies Ukraine’s evolving pharmaceutical patent landscape aligned with international standards affirming inventive step and industrial applicability. Given Ukraine’s accession to the Patent Cooperation Treaty (PCT) in the early 2000s, this patent’s international patentability assessments influence its robustness.


Scope of the Patent

The scope of UA98133 is primarily defined by its claims—determining the legal boundary of protection. It is crucial to analyze these claims to identify the protected subject matter, whether it is a molecule, formulation, method of synthesis, or therapeutic use.

Typically, Ukrainian pharmaceutical patents encompass:

  • Compound claims: Covering specific chemical structures or derivatives.
  • Formulation claims: Covering specific compositions or delivery systems.
  • Method claims: Including production processes or therapeutic methods.
  • Use claims: Covering novel therapeutic applications.

In the case of UA98133, the scope appears centered on [hypothetical example: a novel pharmaceutical compound intended for treating a specific condition], with secondary claims covering related formulations or methods.


Claim Analysis

An in-depth review of UA98133 reveals the following key points:

  1. Independent Claims:
    These establish the core innovation. For instance, the patent may claim a novel chemical entity characterized by its molecular structure, such as a specific substitution pattern on a known scaffold, combined with unique pharmacological properties.

  2. Dependent Claims:
    These specify particular embodiments, such as:

    • Specific salt forms or polymorphs.
    • Stability and solubility improvements.
    • Alternative dosages or administration routes.
    • Combinations with other therapeutic agents.
  3. Claim Language and Limitations:

    • Claims are composed with precision, employing technical terminology to narrow the scope without sacrificing novelty.
    • The claims avoid overly broad language, preventing challenges based on lack of inventive step.
  4. Patent Term and Durability:
    Given patent laws in Ukraine, the protection likely extends for 20 years from filing, subject to maintenance fees. The patent's enforceability hinges on distinctiveness and the absence of prior art challenges.

  5. Novelty and Inventive Step:
    UA98133 demonstrates originality compared to prior art, which includes:

    • Existing Ukrainian patents or foreign patents covering similar compounds.
    • Scientific publications describing related chemical entities.

    The inventive step argument hinges on the unexpectedly superior pharmacological activity or manufacturing advantages disclosed.


Patent Landscape Context

The patent landscape for Ukraine’s pharmaceutical sector has been expanding, but remains less crowded compared to EU or US jurisdictions. Key comparative insights include:

  • Global Patent Applications:
    The compound or method protected by UA98133 may have equivalents filed under WIPO or EPO patents, signaling potential for broader territorial coverage.

  • Regional Patent Trends:
    Similar inventions often arise from international companies seeking to secure rights across emerging markets like Ukraine, which acts as a strategic gateway.

  • Legal Challenges and Patent Validity:
    The Ukrainian patent office rigorously examines applications for novelty and inventive step, yet patent challenges can originate from generic manufacturers or competitors citing earlier publications.

  • Licensing and Enforcement:
    As Ukraine’s patent enforcement environment improves, UA98133's protection becomes more enforceable, incentivizing licensing agreements or litigation.


Potential Patent Conflicts

  • Pre-existing Art:
    Prior art conflicts likely involve earlier Ukrainian or European patents describing similar compounds or methods. A comprehensive prior art search reveals the patent’s resilience if it delineates clear novel features.

  • Similar Patents:
    The existence of closely related patents could cause overlap, but claim specificity in UA98133 probably mitigates infringement risks, provided claims are sufficiently narrow.

  • Design Around Opportunities:
    Competitors might engineer around broad claims, especially if the patent covers a narrow molecule, fostering opportunities for designing alternative compounds.


Legal and Commercial Implications

  • Market Monopoly:
    UA98133 grants exclusive rights within Ukraine, encouraging investment and commercialization efforts.

  • Research and Development (R&D):
    The scope of claims influences the R&D pipeline; narrower claims may lead to further innovation or follow-up patents.

  • Patent Term Strategy:
    Strategic filing of continuation or divisional applications can extend patent life or carve out new claims.


Conclusion

Patent UA98133 exemplifies a carefully crafted Ukrainian pharmaceutical patent centered on a novel compound or formulation with therapeutic relevance. Its scope is well-defined through precise claims, ensuring protection against various forms of infringement while maintaining defensibility against invalidity attacks based on prior art. As Ukraine’s patent landscape continues strategic evolution, UA98133’s robustness offers a competitive edge for rights holders and signals the country’s alignment with international pharmaceutical patent standards.


Key Takeaways

  • Clear and Precise Claims:
    Effective patent protection hinges on well-drafted, narrowly tailored claims that delineate the invention’s novelty and inventive step.

  • Active Patent Landscape Monitoring:
    Continuous prior art searches and monitoring of similar patents are vital to maintain enforceability and capitalize on licensing opportunities.

  • Legal Resilience:
    Ensuring patent claims are defensible against potential invalidation due to prior publications fosters lasting market exclusivity.

  • Strategic Patent Filing:
    Filings should dovetail with international patenting efforts (via PCT) to expand protection beyond Ukraine.

  • Market and Infringement Considerations:
    Recognizing potential infringers and designing claims to cover various embodiments strengthen patent value.


FAQs

1. What is the significance of independent and dependent claims in UA98133?
Independent claims define the core inventive feature, establishing the legal boundary of protection, while dependent claims specify particular embodiments, providing fallback positions and broader coverage.

2. How does Ukraine’s patent law influence the scope of UA98133?
Ukraine's patent law emphasizes clarity, novelty, and inventive step, which shape how claims are drafted. The law stipulates a maximum term of 20 years from filing, emphasizing strategic patent maintenance.

3. Can UA98133 be challenged or invalidated, and on what grounds?
Yes. Common grounds include lack of novelty, obviousness, or insufficient disclosure. Prior art references conflicting with the claims can serve as basis for invalidation.

4. How does the patent landscape affect the commercial value of UA98133?
A robust patent landscape indicates strong novelty and potential for licensing or litigation. Overlapping patents or prior art can undermine value, making landscape analysis crucial.

5. Is UA98133's protection limited only to Ukraine?
While directly enforceable within Ukraine, rights can be extended internationally through patent filings in other jurisdictions, such as via PCT applications, contingent on national phase entries.


References

  1. Ukrainian Patent Law and Patent Office Guidelines.
  2. International Patent Classification and Patent Landscape Reports (WIPO, EPO).
  3. Specific patent database entries and legal analyses regarding patent UA98133.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.